Biodexa Pharmaceuticals (BDRX) Non-Current Deferred Tax Liability (2013 - 2025)

Biodexa Pharmaceuticals has reported Non-Current Deferred Tax Liability for 13 years, with the latest figure at $109.3 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability rose 6.79% year-over-year to $109.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $109.3 million (up 6.79% YoY) and the FY2025 annual result came in at $108.3 million, up 5.86% from the prior year.
• Non-Current Deferred Tax Liability climbed to $109.3 million in Q4 2025 per BDRX's latest filing, from $102.3 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $109.3 million in Q4 2025 and troughed at $83.4 million in Q4 2022.
• A 5-year average of $95.9 million and a median of $93.7 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability declined 7.9% in 2022, then gained 12.35% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $90.6 million in 2021, then decreased by 7.9% to $83.4 million in 2022, then climbed by 12.35% to $93.7 million in 2023, then grew by 9.18% to $102.3 million in 2024, then advanced by 6.79% to $109.3 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $109.3 million, $102.3 million, and $93.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.